Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Receivables (2021 - 2026)

ADC Therapeutics has reported Receivables over the past 6 years, most recently at $31.0 million for Q1 2026.

  • Quarterly results put Receivables at $31.0 million for Q1 2026, down 2.26% from a year ago — trailing twelve months through Mar 2026 was $31.0 million (down 2.26% YoY), and the annual figure for FY2025 was $29.1 million, up 43.32%.
  • Receivables reached $31.0 million in Q1 2026 per ADCT's latest filing, up from $29.1 million in the prior quarter.
  • Across five years, Receivables topped out at $48.8 million in Q4 2022 and bottomed at $26752.0 in Q1 2022.
  • Median Receivables over the past 5 years was $23.9 million (2023), compared with a mean of $24.6 million.
  • The largest annual shift saw Receivables skyrocketed 1003411.3% in 2022 before it plummeted 48.39% in 2023.
  • Over 5 years, Receivables stood at $48.8 million in 2022, then tumbled by 48.39% to $25.2 million in 2023, then dropped by 19.32% to $20.3 million in 2024, then surged by 43.32% to $29.1 million in 2025, then increased by 6.62% to $31.0 million in 2026.
  • Business Quant data shows Receivables for ADCT at $31.0 million in Q1 2026, $29.1 million in Q4 2025, and $22.9 million in Q3 2025.